Table 3.
EpCAM expression in genitourinary tract cancers
| Tumour type (no. of samples) | No EpCAM overexpression* | EpCAM overexpression* | ||||||
| No expression (TIS 0) | Weak expression (TIS 1–4) | Moderate expression (TIS 6, 8) | Intense expression (TIS 9, 12) | |||||
| n | % | n | % | n | % | n | % | |
| Ovarian cancer (326) | 27 | 8 | 63 | 19 | 100 | 31 | 136 | 42 |
| Serous, endometrioid and other histologies (268) | 21 | 8 | 43 | 16 | 87 | 32 | 117 | 44 |
| Mucinous histology (58) | 6 | 10 | 20 | 35 | 13 | 22 | 19 | 33 |
| Renal cancer (122) | 61 | 50 | 14 | 12 | 15 | 12 | 32 | 26 |
| Clear cell histology (48) | 38 | 79 | 4 | 9 | 5 | 10 | 1 | 2 |
| Non-clear-cell histology (74) | 23 | 31 | 10 | 14 | 10 | 14 | 31 | 41 |
| Urothelial cancer (91) | 51 | 56 | 15 | 17 | 21 | 23 | 4 | 4 |
| Endometrial cancer (70) | 4 | 6 | 4 | 6 | 16 | 23 | 46 | 65 |
| Prostate cancer (108) | 1 | 1 | 11 | 10 | 35 | 32 | 61 | 57 |
| SCC of the cervix, vagina and vulva (92) | 54 | 59 | 14 | 15 | 13 | 14 | 11 | 12 |
EpCAM expression was determined by immunohistochemistry.
*
EpCAM overexpression defined by Gastl et al3.
EpCAM, epithelial cell adhesion molecule; SCC, squamous cell cancer; TIS, total immunostaining score.